Tumor lysis with LTX-401 creates anticancer immunity

doi:10.1080/2162402X.2019.1594555

	Tumor lysis with LTX-401 creates anticancer immunity
	Zitvogel, Laurence 14,15,16,17; Levesque, Sarah 3,4,7,8; Pol, Jonathan 3,4,7,8; Mauseth, Brynjar 9,10,11; Mondragon, Laura 3,4,7,8; Xie, Wei 3,4,7,8; Sveinbjornsson, Baldur 2,5,9; Yamazaki, Takahiro 13,14,15,16,17; Eksteen, Johannes J.12; Zhou, Heng 1,3,4,7,8
刊名	ONCOIMMUNOLOGY
	2019-04-12
页码	8
关键词	Oncolysis anticancer therapy immunogenic cell death checkpoint blockade
ISSN号	2162-402X
DOI	10.1080/2162402X.2019.1594555
通讯作者	Kepp, Oliver(captain.olsen@gmail.com)
英文摘要	Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401, yet another oncolytic compound designed for local immunotherapy, depicts a similar safety profile and that sequential local inoculation of LTX-401 was able to cure immunocompetent host from subcutaneous MCA205 and TC-1 cancers. Cured animals exhibited long-term immune memory effects that rendered them resistant to rechallenge with syngeneic tumors. Nevertheless, the local treatment with LTX-401 alone had only limited abscopal effects on secondary contralateral lesions. Anticancer effects resulting from single as well as sequential injections of LTX-401 were boosted in combination with PD-1 and CTLA-4 immune checkpoint blockade (ICB), and sequential LTX-401 treatment combined with double ICB exhibited strong abscopal antineoplastic effects on contralateral tumors underlining the potency of this combination therapy.
资助项目	China Scholarship Council ; Ligue contre le Cancer (equipes labelisees) ; Agence National de la Recherche (ANR) - Projets blancs ; ANR ; Association pour la recherche sur le cancer (ARC) ; Canceropole Ile-de-France ; Institut National du Cancer (INCa) ; Fondation Bettencourt-Schueller ; Fondation de France ; Fondation pour la Recherche Medicale (FRM) ; European Commission (ArtForce) ; European Research Council (ERC) ; LabEx Immuno-Oncology ; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) ; SIRIC Cancer Research and Personalized Medicine (CARPEM) ; Seerave foundation ; Swiss Bridge Foundation ; ISREC ; Paris Alliance of Cancer Research Institutes (PACRI) ; Norwegian Research Council[254800] ; Norwegian Research Council[257967]
WOS关键词	ONCOLYTIC PEPTIDE ; LTX-315 ; CANCER
WOS研究方向	Oncology ; Immunology
语种	英语
出版者	TAYLOR & FRANCIS INC
WOS记录号	WOS:000466670400001
资助机构	China Scholarship Council ; Ligue contre le Cancer (equipes labelisees) ; Agence National de la Recherche (ANR) - Projets blancs ; ANR ; Association pour la recherche sur le cancer (ARC) ; Canceropole Ile-de-France ; Institut National du Cancer (INCa) ; Fondation Bettencourt-Schueller ; Fondation de France ; Fondation pour la Recherche Medicale (FRM) ; European Commission (ArtForce) ; European Research Council (ERC) ; LabEx Immuno-Oncology ; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE) ; SIRIC Cancer Research and Personalized Medicine (CARPEM) ; Seerave foundation ; Swiss Bridge Foundation ; ISREC ; Paris Alliance of Cancer Research Institutes (PACRI) ; Norwegian Research Council
内容类型	期刊论文
源URL	[http://119.78.100.186/handle/113462/133535]
专题	中国科学院近代物理研究所
通讯作者	Kepp, Oliver
作者单位	1.Chinese Acad Sci, Inst Modern Phys, Lanzhou, Gansu, Peoples R China 2.Univ Tromso, Inst Med Biol, Tromso, Norway 3.INSERM, Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France 4.Univ Paris 05, Sorbonne Paris Cite, Paris, France 5.Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden 6.Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France 7.Gustave Roussy Comprehens Canc Inst, Metabol & Cell Biol Platforms, Villejuif, France 8.Univ Paris 06, Paris, France 9.Lytix Biopharma, Oslo, Norway 10.Oslo Univ Hosp, Rikshosp, Div Canc Surg & Transplantat, Oslo, Norway
推荐引用方式 GB/T 7714	Zitvogel, Laurence,Levesque, Sarah,Pol, Jonathan,et al. Tumor lysis with LTX-401 creates anticancer immunity[J]. ONCOIMMUNOLOGY,2019:8.
APA	Zitvogel, Laurence.,Levesque, Sarah.,Pol, Jonathan.,Mauseth, Brynjar.,Mondragon, Laura.,...&Wang, Yan.(2019).Tumor lysis with LTX-401 creates anticancer immunity.ONCOIMMUNOLOGY,8.
MLA	Zitvogel, Laurence,et al."Tumor lysis with LTX-401 creates anticancer immunity".ONCOIMMUNOLOGY (2019):8.